Camlin Fine Sciences Limited (CAMLINFINE) AI Stock Analysis

• Market Cap: ₹29.41B
• Dividend Yield: N/A
• Average Volume (3M): 39.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 9.21%
• EPS Growth: 87.89%
• Country: IN
• Employees: 624
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): -0.10
• Shares Outstanding: 192,086,610
• 10 Day Avg. Volume: 26,894
• 30 Day Avg. Volume: 39,045
• PEG Ratio: -0.48
• Price to Book (P/B): 3.33
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -190.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: ₹161.00 ▲(11.57% Upside)

Camlin Fine Sciences Limited's overall stock score is primarily impacted by its financial performance, which shows stable asset coverage but significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, and valuation is poor due to negative earnings. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Despite profitability issues, modest revenue growth indicates some market demand and potential for future expansion as the company addresses its challenges.

Stable Asset Coverage

A strong equity ratio suggests that the company has a solid asset base, which can provide stability and support future borrowing if needed.

Diverse Revenue Streams

Diverse revenue streams from multiple sectors help mitigate risks associated with dependency on a single market, supporting long-term business resilience.

Negative Factors

Profitability Challenges

Persistent profitability challenges indicate difficulties in cost management or pricing power, potentially impacting long-term sustainability and growth.

Negative Free Cash Flow

Negative free cash flow suggests the company may struggle to fund operations and growth initiatives, which could limit its ability to invest in future opportunities.

Decreased Operating Cash Flow

A significant decrease in operating cash flow can strain financial resources, affecting the company's ability to maintain operations and invest in strategic projects.

Camlin Fine Sciences Limited Business Overview & Revenue Model

Company Description

Camlin Fine Sciences Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of specialty chemical, ingredients, and additive blend products in India and internationally. It offers shelf-life solutions, which include antioxidants comprises Tertiary Butyl Hydroquinone, Butylated Hydroxy Anisole, and Ascorbyl palmitate; and mold inhibitors, preservatives, acidifiers, antibacterial agents, toxin binders, pellet binders, and growth promoters, as well as natural antioxidants, such as mixed tocopherols, green tea extract, rosemary extract, and acerola extract that are used to enhance the shelf life under the Xtendra and NaSure brands. The company also provides aroma ingredients, including vanillin and ethyl vanillin; and nutraceutical products from fermentation and plant extraction sources. In addition, it offers performance chemicals, such as hydroquinone and catechol; and downstream fine chemicals, including Guaiacol, Veratrole, TBC, MEHQ, HQEE, etc. The company also exports its products. Its products are used in food and beverage, pet food and animal nutrition, biodiesel, aquaculture, rendering, petrochemical, agrochemical, pharmaceutical, polymers, dyes and pigment, biscuits and cookies, chocolate and confectionery, fragrance manufacturing, bakery, flavor, electroplating, and dietary supplement industries. The company was formerly known as Camlin Fine Chemicals Limited and changed its name to Camlin Fine Sciences Limited in August 2011. Camlin Fine Sciences Limited was founded in 1931 and is headquartered in Mumbai, India.

How the Company Makes Money

Camlin Fine Sciences generates revenue primarily through the sale of its specialty chemicals and performance products across various industries. Key revenue streams include the production of antioxidants used in food preservation and pharmaceuticals, aroma chemicals for flavor and fragrance applications, and agrochemical intermediates. The company benefits from long-term contracts with major clients and a diverse customer base, which provides a stable income. Additionally, strategic partnerships with industry leaders and ongoing investment in research and development contribute to its financial growth, allowing Camlin Fine Sciences to innovate and expand its product offerings in response to market demand.

Camlin Fine Sciences Limited Financial Statement Overview

Summary

Camlin Fine Sciences Limited shows modest revenue growth but faces significant profitability challenges with negative net profit margins and net income. The balance sheet is stable with moderate leverage, but cash flow constraints are evident, impacting overall financial health.

Income Statement

The revenue growth over the last year was modest at 4.48%. However, the company has struggled with profitability, as indicated by a negative net profit margin of -8.34% for the latest year. This marks a deterioration from the previous year's margin, which was also negative. Gross profit margins have improved slightly, but overall profitability remains weak, evidenced by negative net income for the past two years.

Balance Sheet

The debt-to-equity ratio is approximately 0.76, indicating a moderate level of leverage. Return on equity has turned negative due to the recent net losses, which is concerning. However, the equity ratio is relatively strong at 44.53%, providing some asset coverage. The balance sheet indicates stability in the asset base but highlights challenges in profitability.

Cash Flow

Operating cash flow has significantly decreased from the previous year. Free cash flow has turned negative, reflecting challenges in generating cash relative to capital expenditures. The operating cash flow to net income ratio is positive, suggesting operational activities are still generating cash, but the free cash flow to net income ratio is negative, highlighting cash constraints.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.94B	16.67B	15.95B	16.82B	14.04B	11.81B
Gross Profit	8.97B	7.78B	6.58B	8.41B	6.34B	5.77B
EBITDA	2.54B	1.95B	487.60M	1.84B	1.79B	1.89B
Net Income	-1.15B	-1.39B	-927.53M	521.06M	606.78M	509.63M
Balance Sheet
Total Assets	0.00	20.24B	19.52B	20.60B	18.00B	14.82B
Cash, Cash Equivalents and Short-Term Investments	1.42B	1.92B	812.28M	951.90M	1.29B	1.21B
Total Debt	0.00	6.81B	6.83B	8.01B	6.46B	5.50B
Total Liabilities	-8.75B	11.49B	10.95B	12.36B	10.35B	7.68B
Stockholders Equity	8.75B	9.02B	8.65B	8.19B	7.48B	6.43B
Cash Flow
Free Cash Flow	0.00	-157.24M	784.06M	-934.11M	-683.40M	335.07M
Operating Cash Flow	0.00	267.23M	1.39B	508.98M	1.45B	1.17B
Investing Cash Flow	0.00	-753.50M	-664.98M	-1.25B	-2.49B	-1.33B
Financing Cash Flow	0.00	724.43M	-859.72M	596.58M	1.36B	386.27M

Camlin Fine Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 144.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Negative. The current price of 144.3 is below the 20-day moving average (MA) of 151.96, below the 50-day MA of 160.10, and below the 200-day MA of 208.37, indicating a bearish trend. The MACD of -2.74 indicates Negative momentum. The RSI at 47.09 is Neutral, neither overbought nor oversold. The STOCH value of 44.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAMLINFINE.

Camlin Fine Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROSSARI	70 Outperform	₹31.34B	22.93	―	0.09%	15.47%	-1.72%
BALAMINES	69 Neutral	₹37.71B	25.86	―	0.97%	-10.76%	-27.70%
ADVENZYMES	65 Neutral	₹33.86B	22.96	―	1.70%	14.11%	7.47%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
NEOGEN	54 Neutral	₹29.96B	115.01	―	0.09%	8.44%	-35.59%
PREMEXPLN	54 Neutral	₹27.86B	60.42	―	0.10%	48.22%	90.63%
CAMLINFINE	46 Neutral	₹29.41B	-97.11	―	―	9.21%	87.89%

Camlin Fine Sciences Limited Corporate Events

Camlin Fine Sciences Files SEBI Demat Compliance Certificate for December Quarter

Camlin Fine Sciences Limited has notified the stock exchanges that it has received a confirmation certificate from its registrar and share transfer agent, MUFG Intime India Private Limited, under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 December 2025. The certificate confirms that all securities submitted for dematerialisation during the quarter were duly processed—either accepted or rejected—within prescribed timelines, listed on the relevant exchanges, and that corresponding physical certificates were verified, mutilated, cancelled, and replaced with depository records, underscoring the company’s adherence to regulatory requirements and robust share transfer and demat processes for its investors.

Camlin Fine Sciences Receives GST Order on Ineligible ITC, Plans Appeal

Camlin Fine Sciences has disclosed that it has received an order from the Assistant Commissioner, Office of the Asst./Dy. Commissioner of CGST & Central Excise, Palghar Commissionerate, demanding reversal of allegedly ineligible input tax credit (ITC) totaling Rs 48.58 lakh for FY 2018-19 and 2019-20, along with applicable interest and a 50% penalty under various provisions of the CGST, SGST/MGST and IGST Acts. The order, which relates to purported short or non-reversal of ITC on exempt, nil-rated and non-GST supplies as per discrepancies between GSTR-3B and GSTR-9 filings, is not expected to have a material impact on the company’s financial or operational activities, and the company has stated it is in the process of filing an appeal against the tax demand.

Camlin Fine Sciences Expands Through Strategic Equity Allotment

Camlin Fine Sciences Limited announced the outcome of its Securities Issue and Allotment Committee meeting held on November 30, 2025, where it approved the allotment of 41,06,181 fully paid-up equity shares at a price of ₹247.69 per share. This issuance, amounting to over ₹101 crore, is part of a strategic move to acquire shares in the French company Vinpai, enhancing Camlin’s market position and expanding its international footprint. The transaction increases the company’s paid-up equity share capital, reflecting a significant step in its growth strategy.

Camlin Fine Sciences Expands with Strategic Share Allotment

Camlin Fine Sciences Limited has announced the allotment of 4,106,181 equity shares through a preferential issue to acquire shares of the French company Vinpai. This strategic move, valued at approximately ₹101.71 crore, aims to enhance Camlin’s market position by expanding its product offerings and geographical reach, potentially benefiting stakeholders by increasing the company’s equity share capital and aligning with its growth strategy.

Camlin Fine Sciences Expands Global Reach with Vinpai Acquisition

Camlin Fine Sciences Limited has announced the completion of a significant acquisition involving the allotment of 41,06,181 equity shares to acquire ordinary shares of the French company Vinpai. This strategic move, valued at over ₹101 crore, is expected to strengthen Camlin’s market position by expanding its international footprint and enhancing its product offerings. The new shares will rank equally with existing shares, increasing the company’s paid-up equity share capital and potentially impacting stakeholder value positively.

Camlin Fine Sciences Secures Shareholder Approval for Equity Issuance

Camlin Fine Sciences Limited announced the successful passage of a special resolution through a postal ballot, which involved the issuance of equity shares on a preferential basis as part of a share swap arrangement. The resolution received overwhelming support from shareholders, with a significant majority voting in favor, indicating strong backing for the company’s strategic financial decisions. This move is likely to impact the company’s capital structure and could enhance its market positioning by facilitating strategic partnerships or acquisitions.